Interestingly, CD, m62A, and TQ dose-dependently reduced ADAM17 protein levels in different cancer cells (Figure 2A–I, upper panels), but mRNA levels were not reduced (Figure 2A–I, bottom panels), implying the potential of the three compounds in improving viral susceptibility in patients with malignant tumors. This evidence concerns the gene ADAM17 and cancer.